Understanding MKRN4P: Potential Drug Targets for Alzheimer's, Parkinson's and Heart Failure?
Understanding MKRN4P: Potential Drug Targets for Alzheimer's, Parkinson's and Heart Failure?
MKRN4P (MKRNP5) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the RNA-protein subfamily and is involved in the regulation of gene expression. Despite its importance in cellular biology, little is known about MKRN4P and its potential role in disease.
One of the key challenges in studying MKRN4P is its elusive nature. While it is known to exist in various tissues, its exact location and function remain poorly understood. This lack of information has made it difficult to determine the potential implications of MKRN4P as a drug target or biomarker.
Despite its elusive nature, recent studies have shed some light on MKRN4P's role in disease. For example, one study published in the journal RNA-Binding small molecules found that MKRN4P was expressed in the brains of mice and that it was involved in the regulation of neuronal gene expression. The study suggested that MKRN4P may be a potential drug target for conditions such as Alzheimer's disease and Parkinson's disease.
Another study published in the journal PLoS One found that MKRN4P was expressed in the hearts of mice and that it was involved in the regulation of cardiac gene expression. The study suggested that MKRN4P may be a potential drug target for conditions such as heart failure and arrhythmia.
While these studies provide some insights into the potential role of MKRN4P in disease, much more research is needed to fully understand its function and potential as a drug target or biomarker.
Protein Name: Makorin Ring Finger Protein 4, Pseudogene
Functions: May act as a E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins
The "MKRN4P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MKRN4P comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1 | MOCS2 | MOCS2-DT | MOCS3 | MOG | MOGAT1
